Carbonyl stress induced by intravenous iron during haemodialysis

Nephrology Dialysis Transplantation

Volumn 18, Issue 5, 2003, Pages 924-930

  Michelis, Regina ^a   Gery, Rafi ^a   Sela, Shifra ^a,b   Shurtz Swirski, Revital ^a   Grinberg, Natalie ^a   Snitkovski, Tamara ^a   Shasha, Shaul M ^a,b   Kristal, Batya ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Carbonyl stress; Fibrinogen; Haemodialysis; Intravenous iron therapy; Iron gluconate; Oxidate stress

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; CARBONYL DERIVATIVE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERROUS GLUCONATE; FIBRINOGEN; IRON; PLASMA PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITOMETRY; DERIVATIZATION; DRUG DOSE REGIMEN; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HUMAN; LINEAR SYSTEM; MAINTENANCE THERAPY; MALE; METABOLIC PARAMETERS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; SIDE EFFECT; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANEMIA; CASE-CONTROL STUDIES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TRANSFERRIN;

EID: 0038702032     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg031     Document Type: Article

References (29)

1. Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 2001; 59 [Suppl 78]: S32-S36
2. Miyata T, Ueda Y, Yamada Y et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998; 9: 2349-2356
3. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578
4. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358-363
5. Maier K, Hinze H, Holzer H. Inactivation of enzymes and an enzyme inhibitor by oxidative modification with chlorinated amines and metal-catalyzed oxidation systems. Biochim Biophys Acta 1991; 1079: 238-241
6. Margiloff L, Chaplia L, Chow A, Singhal PC, Mattana J. Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Free Radic Biol Med 1998; 25: 780-785
7. Dalle-Donne I, Rossi R, Giustarini D et al. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic Biol Med 2001; 31: 1075-1083
8. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18: 815-821
9. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease. update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
10. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dialysis Transplant 1999; 14 [Suppl 2]: 61-65
11. Kletzmayr J, Sunder-Plassmann G, Hörl WH. High dose intravenous iron: a note of caution. Nephrol Dial Transplant 2002; 17: 962-965
12. Sela S, Shurtz-Swirski R, Shapiro G et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int 2001; 59 [Suppl 78]: S159-S163
13. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
14. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kid Disease 2001; 37: 750-757
15. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549
16. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
17. Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991; 58: 201-204
18. Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429-437
19. Shacter E. Protein oxidative damage. Methods Enzymol 2000; 319: 428-436
20. Pignatelli B, Li CQ, Boffetta P et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001; 61: 778-784
21. Lupidi G, Angeletti M, Eleuteri AM, Tacconi L, Coletta M, Fioretti E. Peroxynitrite-mediated oxidation of fibrinogen inhibits clot formation. FEBS Lett 1999; 462: 236-240
22. Kirschbaum B. Hypotransferrinemia of chronically hemodialyzed patients. Artif Organs 1999; 23: 1047-1054
23. Jacobs AA, Ward RA, Wellhausen SR, McLeish KR. Polymorphonuclear leukocyte function during hemodialysis: relationship to complement activation. Nephron 1989; 52: 119-124
24. Nissenson A, Lindsay R, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999; 33: 471-482
25. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37: 300-307
26. Sunder-Plassmann G, Hörl W. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-1802
27. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
28. Parkkinen JJ, von Bondorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
29. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin bound iron (NTBI) in dialysis patients. Eur J Clin Inv 2002; 32 [Suppl 1]: 42-49